Did Valneva's Fall Catch You Out? What Bears Saw
Valneva Reports Five-Year Antibody Persistence for Chikungunya Vaccine
Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ®
Valneva Says Single-Dose Chikungunya Vaccine IXCHIQ Showed Antibody Persistence Consistent With Prior Results, In Line With Company Expectations, With 94% Seroresponse At Year 5 Across Age Groups
Valneva Evaluates Next Steps for Bacterial Infection Vaccine Following Successful Phase 2 Studies
Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2
Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026
Declaration of shares and voting rights Status as of October 31, 2026
MHRA revokes approval for Valneva’s Ixchiq due to safety frailties
Full Transcript: Valneva Q2 2026 Earnings Call
UK Revokes Approval for Valneva's Chikungunya Shot
Valneva Shares Fall as UK Withdraws Approval for Ixchiq Chikungunya Vaccine
VALN Stock Plunges 7% After-Hours As UK Revokes Valneva’s IXCHIQ Authorization In Latest Market Setback
Valneva ADRs fall as UK revokes IXCHIQ marketing authorization
Valneva Provides Update on IXCHIQ® in the United Kingdom
Declaration of shares and voting rights - Status as of September 30, 2026
Declaration of shares and voting rights - Status as of August 31, 2026
Valneva (VALN) Q2 2026 Earnings Call Transcript
Valneva: The Lyme Royalty Transition Changes The Earnings Model
Why Did VALN Stock Surge 24% Today?
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.